Visugromab RDE (recommended dose for… (NCT07246863)

Name: Visugromab RDE (recommended dose for expansion) trial for Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT07246863)
Uploaded: 2026-10-31T06:19:35.078Z
Duration: 1 min 19 s
Description: Visugromab RDE (recommended dose for expansion) trial for Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT07246863). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07246863.

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC: a one-minute explainerNCT072468631 min

Visugromab RDE (recommended dose for expansion) trial for Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT07246863). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with metastatic nonsquamous lung cancer that progressed during first-line immunotherapy after at least 12 weeks without progression. No actionable mutation requiring an available targeted drug is allowed.

The idea: visugromab blocks GDF-15 to try to restore immune-cell entry into tumors. Randomized groups receive visugromab/nivolumab with or without docetaxel, or docetaxel with placebos, through intravenous infusions every three weeks.

This phase 2 study plans 131 patients. CatalYm sponsors the trial, with five recruiting US sites. A safety run-in precedes randomization.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.